Attovia Therapeutics, Inc (ATTO) insider trading
Every open-market stock purchase and sale by Attovia Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Colin Walsh (Director) and 5 others bought $77.4M in the last 90 days, more than doubling their stake.
- Goldman Sachs Group Inc (Insider) and 1 other sold $9M in the last 90 days.
Last 12 months: insiders bought $77.4M (8 buys) and sold $9M (4 sales). Last close $14.18 on Oct 21, 2026.
Recent ATTO insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought | $10M |
| Aug 6, 2026 | Goldman Sachs Group Inc (Insider) | Bought | $8.5M |
| Aug 6, 2026 | Colin Walsh (Director) | Bought | $8.5M |
| Aug 6, 2026 | Goldman Sachs Group Inc (Insider) | Bought | $8.5M |
| Aug 6, 2026 | Colin Walsh (Director) | Bought | $8.5M |
| Aug 6, 2026 | Redmile Group LLC (10% owner) | Bought | $6.8M |
| Aug 6, 2026 | venBio Global Strategic Fund IV L.P. (Insider) | Bought | $6.5M |
| Aug 6, 2026 | Sanofi (Insider) | Bought | $5.1M |
| Aug 6, 2026 | Redmile Group LLC (10% owner) | Bought | $3.4M |
| Aug 6, 2026 | Colin Walsh (Director) | Bought (not open market) | — |
| Aug 6, 2026 | Colin Walsh (Director) | Bought (not open market) | — |
| Aug 6, 2026 | Colin Walsh (Director) | Bought (not open market) | — |
| Aug 6, 2026 | Goldman Sachs Group Inc (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Goldman Sachs Group Inc (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Goldman Sachs Group Inc (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Goldman Sachs Group Inc (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Frazier Life Sciences XI L.P. (Insider) | Bought (not open market) | — |
| Aug 6, 2026 | Sanofi (Insider) | Bought (not open market) | — |
Who's trading ATTO
- venBio Global Strategic Fund IV L.P., Insider: bought $6.5M (1 buy), last Aug 6, 2026
- Deep Track Biotechnology Master Fund Ltd., Insider: other filings, last Aug 6, 2026
- Frazier Life Sciences XI L.P., Insider: bought $10M (1 buy), last Aug 6, 2026
- Goldman Sachs Group Inc, Insider: bought $22.8M (10 buys), sold $4.5M (40 sales), last Aug 6, 2026
- Redmile Group LLC, 10% owner: bought $10.2M (2 buys), last Aug 6, 2026
- Sanofi, Insider: bought $5.1M (1 buy), last Aug 6, 2026
- Colin Walsh, Director: bought $22.8M (10 buys), sold $4.5M (40 sales), last Aug 6, 2026
- Petter Veiby, C-suite exec: other filings, last Aug 4, 2026
- Zaneta Odrowaz, C-suite exec: other filings, last Aug 4, 2026
- Steven Chan, CFO: other filings, last Aug 4, 2026
- Hubert Chen, C-suite exec: other filings, last Aug 4, 2026
- Attovia Therapeutics Inc., CFO: other filings, last Aug 4, 2026
- Angie You, Insider: other filings, last Aug 4, 2026
- Tao Fu, CEO: other filings, last Aug 4, 2026
- Mitchell Gold, Insider: other filings, last Aug 4, 2026
Get free alerts when an insider at Attovia Therapeutics, Inc files a new trade →